1. Home
  2. SDGR vs ARQT Comparison

SDGR vs ARQT Comparison

Compare SDGR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SDGR
  • ARQT
  • Stock Information
  • Founded
  • SDGR 1990
  • ARQT 2016
  • Country
  • SDGR United States
  • ARQT United States
  • Employees
  • SDGR N/A
  • ARQT N/A
  • Industry
  • SDGR Biotechnology: Pharmaceutical Preparations
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SDGR Health Care
  • ARQT Health Care
  • Exchange
  • SDGR Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • SDGR 1.3B
  • ARQT 1.1B
  • IPO Year
  • SDGR 2020
  • ARQT 2020
  • Fundamental
  • Price
  • SDGR $18.73
  • ARQT $9.26
  • Analyst Decision
  • SDGR Buy
  • ARQT Strong Buy
  • Analyst Count
  • SDGR 10
  • ARQT 5
  • Target Price
  • SDGR $32.90
  • ARQT $14.40
  • AVG Volume (30 Days)
  • SDGR 910.2K
  • ARQT 2.4M
  • Earning Date
  • SDGR 11-12-2024
  • ARQT 11-06-2024
  • Dividend Yield
  • SDGR N/A
  • ARQT N/A
  • EPS Growth
  • SDGR N/A
  • ARQT N/A
  • EPS
  • SDGR N/A
  • ARQT N/A
  • Revenue
  • SDGR $193,348,000.00
  • ARQT $138,708,000.00
  • Revenue This Year
  • SDGR N/A
  • ARQT $208.32
  • Revenue Next Year
  • SDGR $24.24
  • ARQT $48.56
  • P/E Ratio
  • SDGR N/A
  • ARQT N/A
  • Revenue Growth
  • SDGR N/A
  • ARQT 182.84
  • 52 Week Low
  • SDGR $16.67
  • ARQT $1.76
  • 52 Week High
  • SDGR $38.00
  • ARQT $13.17
  • Technical
  • Relative Strength Index (RSI)
  • SDGR 53.47
  • ARQT 46.45
  • Support Level
  • SDGR $18.42
  • ARQT $8.29
  • Resistance Level
  • SDGR $23.65
  • ARQT $10.76
  • Average True Range (ATR)
  • SDGR 1.00
  • ARQT 0.66
  • MACD
  • SDGR 0.28
  • ARQT 0.09
  • Stochastic Oscillator
  • SDGR 36.87
  • ARQT 32.51

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: